🔎 Trials Near Me

Beranda › Kolitis Ulseratif › Distrik Columbia › Washington

Uji klinis Kolitis Ulseratif di Washington, DC

12 studi untuk Kolitis Ulseratif mencari peserta di lokasi sekitar Washington (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Immune Regulation in Ulcerative Colitis or Crohn s Disease

Menerima pesertaStudi observasionalSukarelawan sehat diterima
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
1 Day – 75 Years · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT00001184

Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease

Menerima pesertaStudi observasional
  • National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT07619547

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Menerima pesertaFase 1
  • MedStar Georgetown University Hospital, Washington D.C.
  • National Cancer Institute Developmental Therapeutics Clinic, Bethesda · 7 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT03816345

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

Menerima pesertaFase 4
  • Capital Digestive Care, Chevy Chase · 8 mi jauhnya
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06581328

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Menerima pesertaFase 3
  • Chevy Chase Clinical Research, Chevy Chase · 8 mi jauhnya
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07196748

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Menerima pesertaFase 3
  • Capital Digestive Care - Chevy Chase, Chevy Chase · 8 mi jauhnya
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937086

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Menerima pesertaFase 4
  • Capital Digestive Care - MGG Group - Chevy Chase Clinical Research, Chevy Chase · 8 mi jauhnya
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06095128

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Menerima pesertaFase 3
  • Mid-Atlantic GI Research, LLC - Site Number: 8400106, Greenbelt · 11 mi jauhnya
Usia 16 hingga 80 · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07184996

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

Menerima peserta
  • MedStar Georgetown University Hospital, Washington D.C.
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT05230173

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Menerima pesertaStudi observasional
  • MGG Group Co., Inc., Chevy Chase Clinical Research, Chevy Chase · 8 mi jauhnya
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT06398626

Therapeutic Endpoint in Pediatric IBD Conditions

Menerima pesertaStudi observasional
  • Children's National Health System, Washington D.C.
Usia 6 hingga 21 · Semua jenis kelamin · Diperbarui 8 Apr 2026 · NCT06065228

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

Menerima pesertaStudi observasional
  • Capital Digestive Care, Chevy Chase · 8 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Mei 2025 · NCT06750731

Uji klinis Kolitis Ulseratif di kota lain

Studi lain di Washington

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.